A Phase 2 interventional study of BMN 111 and Placebo in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 16 sites in 4 countries. Open to participants aged Up to 59 Months. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.
Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 5 in phase 2, and was the 8th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
By country, each count listing its studies:
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: Up to 59 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2018.
This study's enrollment of 75 is close to the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 74 across the 10 interventional studies, 185 across the 4 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have any of the following:
Have a history of any of the following:
Cardiac or vascular disease, including the following
Have evidence of cervicomedullary compression (CMC) likely to require surgical intervention within 60 days of Screening as determined by the Investigator based on the following assessments
Have ever had cervicomedullary decompression surgery (Cohorts 2 and 3 only), spine or long-bone surgery (i.e., surgery involving disruption of bone cortex) or have ever had bone-related surgery with chronic complications
NOTE: Subjects with prior cervicomedullary decompression may be allowed into Cohort 1 only after discussion and agreement with Medical Monitor.
Inclusion Criteria for Cohort 3 Observation Period
Exclusion Criteria for Cohort 3 Observation Period
Have any of the following disorders:
Have a history of any of the following:
Have a history of cardiac or vascular disease, including the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN111 daily.
Drug: BMN 111
Daily subcutaneous injection of placebo
Drug: Placebo
Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
Also known as: Vosoritide, Modified recombinant human C-type natriuretic peptide
Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs)
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. A severity grade was defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. As per CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE. Safety Population includes all sentinel and randomized participants in the FAS who received at least one dose of vosoritide or placebo in this study. Serious adverse event (SAE)
Time frame: Up to Week 56 (Safety Follow-Up +/-7d)
Change From Baseline in Height Z-score at Week 52.
Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased. standard deviation score (SDS). The primary efficacy analysis population was the subset of randomized participants in the FAS.
Time frame: Baseline to Week 52
Change From Baseline in Height at Week 52
As a general rule, standing height/sitting height was used if participants were aged \>= 24 months at baseline. Body length/crown to rump was used if participants were aged \< 24 months at baseline. If body length was not measured and standing height was available, standing height was used.
Time frame: Baseline to Week 52
Change From Baseline in Annualized Growth Velocity (AGV) at Week 52
AGV was derived over 12-month intervals starting from the baseline visit. Annualized growth velocity (AGV) = Standing Height at Date 2 - Standing Height at Date 1/Interval Length (Days) x 365.25. Difference in LS means were obtained from an analysis of covariance model.
Time frame: Baseline to Week 52
Change From Baseline in Upper to Lower Body Segment Ratio at Week 52
Upper to Lower Body ratio=Sitting Height / (Standing Height - Sitting Height).
Time frame: Baseline to Week 52
Change From Baseline in Other Growth Measures (Upper Body Length, Head Circumference, Arm Span, Upper Arm Length, Lower Arm Length, Lower Body Length, Upper Leg Length, Knee to Heel Length, and Tibial Length) at Week 52
Change from baseline in other growth measures (upper body length, head circumference, arm span, upper arm length, lower arm (Forearm) length, Lower Body Length, Upper Leg Length (Thigh), knee to heel length, and tibial length) at Week 52. Participants aged \<24 months, body length and crown to rump length take precedence over standing height and sitting height. Participants aged \<24 months at baseline and \>=24 months at Week 52, body length and crown to rump length take precedence.
Time frame: Baseline to Week 52
Change From Baseline in Other Body Proportion Ratios (Arm Span to Height Ratio, Upper Arm Length to Lower Arm [Forearm] Length Ratio, Upper Leg Length [Thigh] to Knee to Heel Length Ratio, and Upper Leg Length (Thigh) to Tibial Length Ratio) at Week 52
For Height: subjects aged \< 24 months, body length takes precedence over standing height. Subjects aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.
Time frame: Baseline to Week 52
Change From Baseline in Body Mass Index (BMI) at Week 52
Body Mass Index (BMI): For height used for BMI calculation, participants aged \< 24 months, body length takes precedence over standing height. Participants aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.
Time frame: Baseline to Week 52
Change From Baseline in BMI Z-score at Week 52
The body mass index (BMI) Z-score represents the participant's BMI converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean BMI for age and sex of the reference population. A positive BMI Z-score means BMI is above the mean BMI for the average stature population of the same sex and age and a negative BMI Z-Score means BMI is below the mean BMI for the average stature population of the same sex and age. BMI Z-scores are derived only for participants aged 24 months or older, the change from baseline to Week 52 in BMI Z-score is summarized for Cohort 1 only as no participants in Cohort 2 or Cohort 3 were 24 months at baseline.
Time frame: Baseline to Week 52
Change From Baseline in Weight Z-score at Week 52
The weight Z-score represents the participant's weight converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean weight for age and sex of the reference population. A positive weight Z-score means weight is above the mean weight for the average stature population of the same sex and age and a negative weight Z-Score means weight is below the mean weight for the average stature population of the same sex and age.
Time frame: Baseline to Week 52
Change From Baseline in Infant Toddler Quality of Life (ITQoL) Scores at Week 52
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health).
Time frame: Baseline to Week 52
Change From Baseline in ITQoL-Behavior Scores at Week 52
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
Time frame: Baseline to Week 52
Change From Baseline in ITQoL-Global Behavior Scores at Week 52
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global behaviour. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
Time frame: Baseline to Week 52
Change From Baseline in ITQoL-Getting On With Other Score at Week 52
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global health perceptions. The number of subjects assessed in Cohort 3 Placebo and Cohort 3 vosoritide are 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
Time frame: Baseline to Week 52
Change From Baseline in ITQoL-Health Score at Week 52
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global change in health. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
Time frame: Baseline to Week 52
Change From Baseline in Functional Independence Measure for Children (WeeFIM-II) Score at Week 52
The Pediatric Functional Independence Measure-II (WeeFIM®-II) is designed to measure functional independence of children between the ages of 6 months \& 18 yrs who have physical or general developmental limitations. The WeeFIM-II is comprised of 3 domains that are rated by clinicians based on information obtained from parents/caregivers (self-care \[score range 8 to 56\], mobility \[score range 8 to 35\], \& cognition \[score range 8 to 35\]) \& provides a total score between 18 (worst) \& 126 (Best). Higher score reflects higher level of independence. Performance of a child on each of individual items within WeeFIM is assigned to one of seven levels on an ordinal scale that represent function from complete \& modified independence (levels 7 \& 6) without a helping person to modified \& complete dependence (levels 5 to 1) with a helping person. Functional Independence Measure (Wee-FIM-II) is only validated in children ages 6 months to 18 yrs. Therefore results for Cohort 3 is not summarized.
Time frame: Baseline to Week 52
Change From Baseline in Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) Scores at Week 52
BSID-III is performance-based clinician-reported outcome assessment for use in children from 1 to 42 months (1 month to 3.5 years). individually administered by the trained clinician to the participant/child Scales include Cognitive subscale, Receptive and Expressive subscales, and Gross and Fine Motor subscales. The two language scales make up a composite Language Scale score and the Gross and Fine Motor subscales yield a composite Motor Scale score. In addition, there is a Social-Emotional Scale and Adaptive Behavior Scale, which is a questionnaire read and completed by parent or caregiver. Scores range from 0 to 2, and indicate mastery (2), emerging (1) or zero (not present) Each (sub)scale yields a total raw score, standardized according to the participant's chronological age (scaled scores)
Time frame: Baseline to Week 52
Change From Baseline in Child Behaviour Checklist (CBCL) at Week 52
The CBCL is used as a screening tool for emotional or behavioral problems, measuring initial behavior severity, tracking changes in behavioral problems over the course of treatment, and treatment planning. The CBCL 1.5-5 years old consists of 100 questions, scored on a three-point Likert scale (0=Not True (as far as you know), 1= Somewhat or Sometimes True, 2=Very True or Often True). The scores for each individual question within a domain are summed to give a domain score. The CBCL uses a normative sample to create standard scores, which are scaled so that 50 is average with a standard deviation of 10, where higher scores indicate more emotional or behavioral issues. CBCL was waived for children \< 18 months old. Therefore results for Cohort 3 is not summarized.
Time frame: Baseline to Week 52
Change From Baseline in Bilateral X-rays of Lower Extremities at Week 52
Time frame: Baseline to Week 52
Change From Baseline in Bilateral X-rays of Left/Right Tibia Bowing Angle at Week 52
Time frame: Baseline to Week 52
Change From Baseline in Bilateral X-rays of Left Femur Length (cm) to Tibia Length (cm) Ratio and Right Femur Length (cm) to Tibia Length (cm) Ratio at Week 52
Time frame: Baseline to Week 52 End point timeframe:
Change From Baseline in Bilateral X-rays of Left Tibia Length (cm) to Fibula Length (cm) Ratio & Right Tibia Length (cm) to Fibula Length (cm) Ratio at Week 52
Time frame: Baseline to Week 52
Change From Baseline in X-ray of Lumbar Spine Vertebral Ratios at Week 52
Time frame: Baseline to Week 52
Change From Baseline in X-ray of Lumbar Spine Transverse Diameter at Week 52
Time frame: Baseline to Week 52
Change From Baseline in X-ray of Lumbar Spine Sagittal Width and Week 52
Baseline is defined as Day 1 or screening if a Day 1 assessment is not available.
Time frame: Baseline to Week 52
Change From Baseline in X-ray of Lumbar Spine Angles at Week 52
Time frame: Baseline to Week 52
Changes From Baseline in X-ray of Lumbar Spine Angle Changes: Number of Participants With an Increase in Lumbar Spine Angle at Week 52
Percentages were calculated using the total number of subjects in the safety population (N for each treatment group) as the denominator. All increases are comparing results at Week 52 relative to the baseline assessment.
Time frame: Baseline to Week 52
MRI Parameter: Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.
Time frame: Baseline to Week 52
MRI Parameter: Percentage Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.
Time frame: Baseline to Week 52
MRI Parameter: Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level
Time frame: Baseline to Week 52
MRI Parameter: Percentage Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level
Time frame: Baseline to Week 52
MRI Parameter: Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus
Time frame: Baseline to Week 52
MRI Parameter: Percentage Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus
Time frame: Baseline to Week 52
Dual X Ray Absorptiometry (DEXA) Parameter: Change From Baseline to Week 52 for Whole Body Less Head Bone Mineral Content (BMC)
Time frame: Baseline to Week 52
DEXA Parameter: Change From Baseline to Week 52 of Whole Body Less Head Bone Mineral Density (BMD)
Time frame: Baseline to Week 52
DEXA Parameter: Change From Baseline to Week 52 of Whole Body BMC
Time frame: Baseline to Week 52
DEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMC
Time frame: Baseline to Week 52
DEXA Parameter: Change From Baseline to Week 52 of Whole Body BMD
Time frame: Baseline to Week 52
DEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMD
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Whole Body BMD Z-score
Hologic - Discovery Horizon Whole Body BMD Z-Score. Change in whole body bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A whole body BMD Z-score \<-2 SD can indicate low bone density in children. The Whole Body BMD (bone mineral density) z-score compares the BMD to the average bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis.
Time frame: Baseline to Week 52
Change From Baseline to Week 52 in Lumbar Spine BMD Z-Score
Hologic - Discovery Horizon Lumbar Spine BMD Z-Score Change in lumbar spine bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants lumbar spine BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A BMD Z-score \<-2 SD can indicate low bone density in the lumbar spine in children. The Lumbar Spine BMD (bone mineral density) z-score compares the BMD in the lumbar spine to the average spinal bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis of the spine.
Time frame: Baseline to Week 52
Immunogenicity: Number of Participants With Incidence of Antibody Positivity at Scheduled Visits
Number of participants with Incidence of Antibody Positivity at Scheduled Visits for : total antibody (TAb), Neutralizing antibodies (NAb), atrial natriuretic peptide (ANP), B-type Natriuretic Peptide (BNP) \& C-type natriuretic peptide (CNP). TAb Titer Positive, NAb Titer Positive, ANP Reactivity Positive, BNP Reactivity Positive \& CNP Reactivity Positive. Day 1 is the baseline assessment result taken prior to first dose of study drug. Ever Positive = the number of participants with at least one positive sample result.
Time frame: At Day 1, Week 3, Week 13, Week 26, Week 52, & Ever Positive.
Biomarker: Bone Specific Alkaline Phosphatase (BSAP) Overtime
Time frame: At Baseline, Day 8, Week 6, Week 20, & Week 39.
Biomarker: Type II Collagen C-Telopeptides Normalized for Creatinine (CTX-II)
Time frame: Baseline to Week 52.
Biomarker: Plasma Cyclic Guanosine Monophosphate (cGMP) Change From Pre-Dose to Maximum Post-Dose at Week 52
Time frame: Week 52 Pre-Dose to Week 52 Maximum Post-Dose.
Biomarker: Bone and Collagen Metabolism Biomarker Over Time-CNP Col X BM
Laboratory results up to 30 days after study drug discontinuation were included. Baseline is the last measurement prior to the initiation of study drug.
Time frame: At Baseline, Day 8, Week 6, Week 20, & Week 39.
Change in Sleep Study Indices at Week 52
Sleep-testing device was used to assess presence \& severity of sleep-disordered breathing by measurement of blood oxygen(O2)saturation,pulse rate,\& airflow during overnight monitoring Episodes(Epi) of sleep apnea variables summarized as: Number(No.)of epi of apnea/hr(AI);No.of epi of hypopnea/hr(HI);No.of epi of obstructive apnea hypopneas/hr(AHI);No.of epi of obstructive apneas/hr(Obstructive Apnea Index);No.of epi of central apneas/hr(CAI);No.of desaturations/hr \>=3% AHI is a marker of obstructive sleep apnea (OSA), scored as No.of apnea or hypopnea epi/hr, with AHI \<=1/hr normal, 1\< AHI\<=5 mild,5\< AHI \<=10 moderate,\& AHI\>10/hr severe OSA. CAI reflects cervical cord compression at cervical-medullary junction, \& is No. of epi of a pause in ventilation with no associated respiratory effort, with\> 5 epi/hr abnormal.O2 desaturation index measures average No. of desaturation epi/hr, defined as decrease in O2 saturation of \>=3% for at least 10sec, with(\<8/hr normal \& \>=8/hr abnormal
Time frame: Baseline to Week 52
PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞) at Day1, Week 13, Week 26, Week 39, & Week 52
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞ excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
Time frame: At Day1, Week 13, Week 26, Week 39, & Week 52.
PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Nominal 120 Minutes Postdose (AUC 0- 120 Min) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52
PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-t) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52
PK Parameter: Maximum Observed Plasma Concentration (Cmax) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52
PK Parameter: Time to Reach Maximum Concentration (Tmax) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.
PK Parameter: Apparent Clearance (CL/F) at Day 01, Week 13, Week 26, Week 39, & Week 52
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.
PK Parameter: Apparent Volume of Distribution (Vz/F) at Day 01, Week 13, Week 26, Week 39, & Week 52
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. V/F excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.
PK Parameter: Elimination Half-life (t1/2) at Day 01, Week 13, Week 26, Week 39, & Week 52
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.
This was a multi-center study conducted by 16 principal investigators at 16 study centers in four countries (United States, Australia, United Kingdom and Japan).
| Milestone | Sentinel | Randomized Vosoritide | Randomized Placebo |
|---|---|---|---|
| Started | 11 | 32 | 32 |
| Cohort 1: age >= 24 to < 60 months | 4 | 15 | 16 |
| Cohort 2: age >= 6 to < 24 months | 4 | 8 | 8 |
| Cohort 3: age 0 to < 6 months | 3 | 9 | 8 |
| Completed | 11 | 31 | 31 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Ae of sudden infant death syndrome, not related | 0 | 1 | 0 |
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. A severity grade was defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. As per CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE. Safety Population includes all sentinel and randomized participants in the FAS who received at least one dose of vosoritide or placebo in this study. Serious adverse event (SAE)
| Participants | Sentinel | Randomized Vosoritide | Randomized Placebo |
|---|---|---|---|
| Participants with any AE | 11 | 32 | 32 |
| Participants with any SAE | 0 | 3 | 6 |
| Participants with any treatment-related AE | 8 | 29 | 17 |
| Participants with any treatment-related SAEs | 0 | 0 | 0 |
| Participants with any AE of CTCAE grade >=3 | 0 | 2 | 3 |
| Participants who died | 0 | 1 | 0 |
Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased. standard deviation score (SDS). The primary efficacy analysis population was the subset of randomized participants in the FAS.
| Z-score | Randomized Vosoritide | Randomized Placebo | All Vosoritide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Height Z-score at Week 52. | -0.06 (-0.26 to 0.15) | -0.31 (-0.48 to -0.13) | 0.01 (-0.15 to 0.17) | -0.30 (-0.47 to -0.13) |
As a general rule, standing height/sitting height was used if participants were aged \>= 24 months at baseline. Body length/crown to rump was used if participants were aged \< 24 months at baseline. If body length was not measured and standing height was available, standing height was used.
| cm | Randomized Vosoritide | Randomized Placebo | All Vosoritide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Height at Week 52 | 8.15 (7.55 to 8.75) | 7.38 (6.87 to 7.89) | 8.41 (7.93 to 8.89) | 7.45 (6.95 to 7.95) |
AGV was derived over 12-month intervals starting from the baseline visit. Annualized growth velocity (AGV) = Standing Height at Date 2 - Standing Height at Date 1/Interval Length (Days) x 365.25. Difference in LS means were obtained from an analysis of covariance model.
| cm/year | Randomized Vosoritide | Randomized Placebo | All Vosoritide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 | -2.17 (-2.76 to -1.58) | -2.95 (-3.45 to -2.45) | -2.41 (-2.88 to -1.94) | -3.32 (-3.81 to -2.84) |
Upper to Lower Body ratio=Sitting Height / (Standing Height - Sitting Height).
| Ratio | Randomized Vosoritide | Randomized Placebo | All Vosoritide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Upper to Lower Body Segment Ratio at Week 52 | -0.20 (-0.28 to -0.13) | -0.13 (-0.21 to -0.06) | -0.19 (-0.25 to -0.13) | -0.13 (-0.20 to -0.06) |
Change from baseline in other growth measures (upper body length, head circumference, arm span, upper arm length, lower arm (Forearm) length, Lower Body Length, Upper Leg Length (Thigh), knee to heel length, and tibial length) at Week 52. Participants aged \<24 months, body length and crown to rump length take precedence over standing height and sitting height. Participants aged \<24 months at baseline and \>=24 months at Week 52, body length and crown to rump length take precedence.
| cm | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Upper body length | 3.04 ± 1.52 | 3.54 ± 1.81 | 5.45 ± 1.75 | 5.20 ± 1.50 | 6.58 ± 0.99 | 6.75 ± 0.86 |
| Head Circumference | 0.68 ± 0.66 | 0.74 ± 0.49 | 2.29 ± 1.28 | 3.10 ± 1.45 | 5.35 ± 0.71 | 6.29 ± 0.81 |
| Arm Span | 4.86 ± 1.99 | 5.82 ± 3.65 | 7.13 ± 1.59 | 7.22 ± 1.45 | 8.22 ± 1.93 | 8.99 ± 4.77 |
| Upper Arm Length | 1.02 ± 1.13 | 0.77 ± 0.96 | 1.08 ± 0.93 | 1.44 ± 1.26 | 1.95 ± 1.23 | 1.44 ± 1.33 |
| Lower Arm (Forearm) Length | 0.49 ± 0.96 | 0.79 ± 0.90 | 1.78 ± 0.44 | 1.57 ± 0.98 | 1.66 ± 0.82 | 1.49 ± 0.79 |
| Lower Body Length | 2.41 ± 1.31 | 2.89 ± 1.99 | 2.39 ± 1.27 | 3.79 ± 1.56 | 3.86 ± 1.55 | 4.41 ± 1.53 |
| Upper Leg Length (Thigh) | 0.82 ± 1.75 | 1.55 ± 1.46 | 0.38 ± 1.71 | 1.10 ± 1.42 | 1.98 ± 2.21 | 1.93 ± 1.65 |
| Knee to Heel Length | 1.52 ± 0.76 | 2.21 ± 0.67 | 2.70 ± 0.75 | 2.29 ± 1.91 | 2.93 ± 0.68 | 3.12 ± 0.85 |
| Tibial Length | 0.85 ± 0.69 | 1.16 ± 1.35 | 1.97 ± 1.49 | 1.99 ± 0.80 | 1.83 ± 0.88 | 1.39 ± 0.77 |
For Height: subjects aged \< 24 months, body length takes precedence over standing height. Subjects aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.
| Ratio | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Upper Arm Length to Lower Arm(Forearm)Length Ratio | 0.05 ± 0.15 | 0.00 ± 0.12 | -0.09 ± 0.06 | 0.01 ± 0.10 | 0.02 ± 0.11 | -0.01 ± 0.12 |
| Upper Leg Length(Thigh)-Knee to Heel Length Ratio | -0.01 ± 0.08 | 0.01 ± 0.07 | -0.09 ± 0.10 | -0.03 ± 0.08 | 0.01 ± 0.16 | -0.02 ± 0.11 |
| Upper Leg Length (Thigh) to Tibial Length Ratio | 0.00 ± 0.12 | 0.02 ± 0.17 | -0.16 ± 0.24 | -0.10 ± 0.07 | 0.00 ± 0.29 | 0.04 ± 0.22 |
| Arm Span to Standing Height Ratio | 0.00 ± 0.02 | 0.00 ± 0.06 | 0.00 ± 0.02 | -0.01 ± 0.02 | -0.01 ± 0.04 | -0.02 ± 0.07 |
Body Mass Index (BMI): For height used for BMI calculation, participants aged \< 24 months, body length takes precedence over standing height. Participants aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.
| kg/m^2 | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at Week 52 | 0.20 ± 1.34 | -0.45 ± 0.94 | 0.55 ± 1.17 | 0.08 ± 0.75 | 0.74 ± 1.70 | 0.94 ± 1.42 |
The body mass index (BMI) Z-score represents the participant's BMI converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean BMI for age and sex of the reference population. A positive BMI Z-score means BMI is above the mean BMI for the average stature population of the same sex and age and a negative BMI Z-Score means BMI is below the mean BMI for the average stature population of the same sex and age. BMI Z-scores are derived only for participants aged 24 months or older, the change from baseline to Week 52 in BMI Z-score is summarized for Cohort 1 only as no participants in Cohort 2 or Cohort 3 were 24 months at baseline.
| Z-Score | Cohort 1: Placebo | Cohort 1: Vosoritide |
|---|---|---|
| Change From Baseline in BMI Z-score at Week 52 | -0.12 ± 0.48 | -0.18 ± 0.65 |
The weight Z-score represents the participant's weight converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean weight for age and sex of the reference population. A positive weight Z-score means weight is above the mean weight for the average stature population of the same sex and age and a negative weight Z-Score means weight is below the mean weight for the average stature population of the same sex and age.
| Z-score | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Change From Baseline in Weight Z-score at Week 52 | 0.14 ± 0.44 | 0.14 ± 0.42 | 0.74 ± 0.82 | 0.70 ± 0.64 | -0.81 ± 0.49 | -0.66 ± 0.77 |
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health).
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Overall Health Score | 3.75 ± 17.60 | 4.33 ± 15.10 | -5.00 ± 15.41 | -3.50 ± 14.15 | -5.00 ± 7.75 | 0.50 ± 13.01 |
| Physical Abilities Score | -6.01 ± 9.83 | 8.82 ± 23.06 | 3.36 ± 8.62 | 1.30 ± 16.05 | 2.35 ± 29.29 | -15.91 ± 22.74 |
| Growth and Development Scores | 4.82 ± 11.62 | 4.34 ± 9.40 | -0.71 ± 8.75 | 1.46 ± 26.01 | 3.57 ± 6.35 | -3.50 ± 13.19 |
| Pain Score | -1.19 ± 20.37 | -1.47 ± 18.22 | -1.19 ± 18.90 | -7.64 ± 27.63 | -4.69 ± 27.77 | 2.50 ± 22.58 |
| Temperament and mood Score | 4.79 ± 9.60 | 0.54 ± 5.40 | 0.66 ± 7.18 | -0.49 ± 9.78 | -2.43 ± 6.76 | 4.62 ± 10.48 |
| Global health perceptions score | -1.07 ± 15.43 | 2.24 ± 12.37 | -2.73 ± 11.29 | -4.55 ± 12.18 | -2.84 ± 13.62 | 0.50 ± 17.11 |
| Parental impact emotional score | 2.04 ± 23.13 | -0.84 ± 8.89 | 0.51 ± 14.64 | -6.85 ± 11.94 | 9.82 ± 20.89 | -2.50 ± 19.05 |
| Parental Impact Time Score | 9.52 ± 29.06 | 4.76 ± 10.78 | -8.05 ± 19.70 | -2.38 ± 35.61 | -10.7 ± 17.59 | 2.38 ± 14.93 |
| Family Cohesion Score | 1.79 ± 13.53 | -1.25 ± 10.72 | 0.00 ± 15.00 | -7.08 ± 28.08 | -3.13 ± 8.84 | -4.50 ± 15.54 |
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Vosoritide | Cohort 3 Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in ITQoL-Behavior Scores at Week 52 | 2.73 ± 23.36 | 0.37 ± 9.50 | 1.74 ± 13.60 | -3.39 ± 7.46 | 0.00 ± NA | — |
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global behaviour. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Vosoritide | Cohort 3: Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in ITQoL-Global Behavior Scores at Week 52 | 1.15 ± 21.42 | 0.29 ± 18.58 | 3.00 ± 12.55 | -10.56 ± 21.71 | -15.00 ± NA | — |
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global health perceptions. The number of subjects assessed in Cohort 3 Placebo and Cohort 3 vosoritide are 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Change From Baseline in ITQoL-Getting On With Other Score at Week 52 | 7.78 ± 17.18 | 1.74 ± 8.88 | 2.33 ± 7.22 | 0.82 ± 5.35 | — | — |
97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global change in health. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Vosoritide | Cohort 3: Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in ITQoL-Health Score at Week 52 | 0.08 ± 0.64 | 0.13 ± 0.62 | -0.60 ± 1.34 | 0.33 ± 0.52 | 0.00 ± NA | — |
The Pediatric Functional Independence Measure-II (WeeFIM®-II) is designed to measure functional independence of children between the ages of 6 months \& 18 yrs who have physical or general developmental limitations. The WeeFIM-II is comprised of 3 domains that are rated by clinicians based on information obtained from parents/caregivers (self-care \[score range 8 to 56\], mobility \[score range 8 to 35\], \& cognition \[score range 8 to 35\]) \& provides a total score between 18 (worst) \& 126 (Best). Higher score reflects higher level of independence. Performance of a child on each of individual items within WeeFIM is assigned to one of seven levels on an ordinal scale that represent function from complete \& modified independence (levels 7 \& 6) without a helping person to modified \& complete dependence (levels 5 to 1) with a helping person. Functional Independence Measure (Wee-FIM-II) is only validated in children ages 6 months to 18 yrs. Therefore results for Cohort 3 is not summarized.
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide |
|---|---|---|---|---|
| WeeFIM-II Total Score | 11.2 ± 11.1 | 14.7 ± 17.3 | 16.2 ± 14.6 | 16.5 ± 28.1 |
| WeeFIM : Self-Care Score | 6.4 ± 6.0 | 6.6 ± 7.2 | 3.7 ± 2.3 | 5.6 ± 14.1 |
| WeeFIM: Mobility Score | 2.2 ± 3.4 | 4.5 ± 5.6 | 7.0 ± 7.5 | 6.7 ± 9.4 |
| WeeFIM: Cognitive Score | 2.6 ± 4.0 | 3.6 ± 6.0 | 5.5 ± 7.6 | 4.2 ± 8.4 |
BSID-III is performance-based clinician-reported outcome assessment for use in children from 1 to 42 months (1 month to 3.5 years). individually administered by the trained clinician to the participant/child Scales include Cognitive subscale, Receptive and Expressive subscales, and Gross and Fine Motor subscales. The two language scales make up a composite Language Scale score and the Gross and Fine Motor subscales yield a composite Motor Scale score. In addition, there is a Social-Emotional Scale and Adaptive Behavior Scale, which is a questionnaire read and completed by parent or caregiver. Scores range from 0 to 2, and indicate mastery (2), emerging (1) or zero (not present) Each (sub)scale yields a total raw score, standardized according to the participant's chronological age (scaled scores)
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Motor Composite Score | -2.0 ± 5.7 | 4.8 ± 11.5 | 12.0 ± 17.5 | -2.3 ± 12.3 | 5.4 ± 22.2 | 11.1 ± 18.1 |
| Cognitive scaled score | -1.0 ± 2.8 | -0.5 ± 1.7 | 3.3 ± 4.9 | 0.6 ± 3.2 | 1.5 ± 1.9 | 2.1 ± 4.4 |
| Cognitive composite score | -5.0 ± 14.1 | -2.5 ± 8.7 | 16.7 ± 24.7 | 3.1 ± 16.0 | 7.5 ± 9.4 | 10.6 ± 22.1 |
| Receptive communication language scaled score | -1.0 ± 0.0 | -1.8 ± 2.5 | 3.3 ± 4.0 | 1.0 ± 1.2 | -3.0 ± 2.1 | 0.7 ± 5.2 |
| Expressive communication language scaled score | 2.5 ± 0.7 | 0.3 ± 1.3 | 2.8 ± 2.9 | -0.1 ± 2.2 | -1.8 ± 1.6 | -0.1 ± 3.3 |
| Language sum of scaled score | 1.5 ± 0.7 | -1.5 ± 3.3 | 6.0 ± 5.2 | 1.8 ± 4.0 | -7.3 ± 6.4 | -0.3 ± 6.6 |
| Language composite score | 4.5 ± 2.1 | -4.5 ± 9.9 | 17.8 ± 15.2 | 5.3 ± 12.1 | -13.4 ± 5.8 | -0.9 ± 19.5 |
| Fine motor scaled score | -0.5 ± 3.5 | 0.0 ± 2.9 | 1.5 ± 3.3 | -2.1 ± 2.5 | 2.2 ± 4.8 | 2.6 ± 2.7 |
| Gross motor scaled score | 0.0 ± 5.7 | 1.0 ± 0.8 | 2.8 ± 3.2 | 1.3 ± 2.8 | -0.2 ± 3.1 | 0.1 ± 3.0 |
The CBCL is used as a screening tool for emotional or behavioral problems, measuring initial behavior severity, tracking changes in behavioral problems over the course of treatment, and treatment planning. The CBCL 1.5-5 years old consists of 100 questions, scored on a three-point Likert scale (0=Not True (as far as you know), 1= Somewhat or Sometimes True, 2=Very True or Often True). The scores for each individual question within a domain are summed to give a domain score. The CBCL uses a normative sample to create standard scores, which are scaled so that 50 is average with a standard deviation of 10, where higher scores indicate more emotional or behavioral issues. CBCL was waived for children \< 18 months old. Therefore results for Cohort 3 is not summarized.
| Score on a scale | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide |
|---|---|---|---|---|
| CBCL Pre-School : Emotionally Reactive Total | -0.2 ± 1.5 | 0.1 ± 1.4 | 1.0 ± 2.0 | 1.0 ± 3.9 |
| CBCL Pre-School : Anxious/Depressed Total | 0.3 ± 1.7 | 0.2 ± 1.4 | 0.0 ± 2.2 | 0.8 ± 3.1 |
| CBCL Pre-School : Withdrawn Total | -0.6 ± 1.7 | 0.6 ± 1.5 | 0.8 ± 2.2 | -0.2 ± 1.6 |
| CBCL Pre-School : Somatic Complaints Total | 0.1 ± 1.7 | 0.3 ± 1.0 | 0.5 ± 1.0 | 1.8 ± 4.1 |
| CBCL Pre-School : Sleep Problems Total | -0.3 ± 3.2 | 0.1 ± 1.9 | -0.3 ± 1.7 | 1.4 ± 4.3 |
| CBCL Pre-School : Attention Problems Total | -0.1 ± 1.9 | -0.1 ± 1.6 | -0.3 ± 1.0 | -0.2 ± 2.0 |
| CBCL Pre-School : Aggressive Behavior Total | -1.1 ± 2.4 | 0.3 ± 4.1 | -0.8 ± 1.5 | -0.4 ± 2.7 |
| CBCL Pre-School : Total Problems Total | -3.0 ± 13.0 | 2.8 ± 11.7 | -2.3 ± 6.0 | 3.6 ± 23.2 |
| cm | All Vosoritide | Placebo |
|---|---|---|
| Left Femur Length | 2.29 ± 0.58 | 2.01 ± 0.62 |
| Right Femur Length | 2.35 ± 0.49 | 2.20 ± 0.73 |
| Left Fibula Length | 2.00 ± 0.61 | 1.97 ± 0.69 |
| Right Fibula Length | 2.00 ± 0.64 | 1.89 ± 0.75 |
| Left Tibia Length | 1.92 ± 0.55 | 1.69 ± 0.70 |
| Right Tibia Length | 1.96 ± 0.57 | 1.68 ± 0.77 |
| Left Distance Between Ankle Joint and Distal Growth Plate of Fibula | -0.02 ± 0.23 | 0.07 ± 0.23 |
| Right Distance Between Ankle Joint and Distal Growth Plate of Fibula | -0.05 ± 0.23 | 0.05 ± 0.22 |
| Left Lower Extremity | 6.02 ± 6.67 | 3.87 ± 1.56 |
| Right Lower Extremity | 6.08 ± 6.54 | 4.26 ± 1.85 |
| Degrees | All Vosoritide | Placebo |
|---|---|---|
| Left Tibia Bowing Angle | -0.97 ± 5.88 | 1.07 ± 5.38 |
| Right Tibia Bowing Angle | -2.34 ± 5.37 | -0.93 ± 5.54 |
| Ratio | All Vosoritide | Placebo |
|---|---|---|
| Left Femur Length (cm) to Tibia Length (cm) Ratio | -0.03 ± 0.06 | -0.05 ± 0.05 |
| Right Femur Length (cm) to Tibia Length (cm) Ratio | -0.05 ± 0.06 | -0.02 ± 0.03 |
| Ratio | All Vosoritide | Placebo |
|---|---|---|
| Left Tibia Length (cm) to Fibula Length (cm) Ratio | -0.02 ± 0.04 | -0.04 ± 0.04 |
| Right Tibia Length (cm) to Fibula Length(cm) Ratio | -0.02 ± 0.05 | -0.03 ± 0.04 |
| Ratio | All Vosoritide | Placebo |
|---|---|---|
| Anterior Height to Medial Height Ratio (L1) | -0.04 ± 0.16 | -0.04 ± 0.20 |
| Anterior Height to Medial Height Ratio (L2) | -0.06 ± 0.16 | -0.07 ± 0.16 |
| Anterior Height to Medial Height Ratio (L3) | -0.02 ± 0.19 | 0.04 ± 0.09 |
| Anterior Height to Medial Height Ratio (L4) | 0.02 ± 0.12 | -0.01 ± 0.11 |
| Anterior Height to Medial Height Ratio (L5) | -0.02 ± 0.15 | 0.04 ± 0.17 |
| Anterior Height to Posterior Height Ratio (L1) | -0.03 ± 0.13 | -0.08 ± 0.17 |
| Anterior Height to Posterior Height Ratio (L2) | -0.02 ± 0.13 | -0.03 ± 0.12 |
| Anterior Height to Posterior Height Ratio (L3) | -0.01 ± 0.16 | 0.04 ± 0.12 |
| Anterior Height to Posterior Height Ratio (L4) | 0.03 ± 0.11 | 0.02 ± 0.13 |
| Anterior Height to Posterior Height Ratio (L5) | 0.01 ± 0.13 | 0.02 ± 0.15 |
| Medial Height to Posterior Height Ratio (L1) | -0.01 ± 0.15 | -0.04 ± 0.12 |
| Medial Height to Posterior Height Ratio (L2) | 0.05 ± 0.11 | 0.03 ± 0.09 |
| Medial Height to Posterior Height Ratio (L3) | -0.02 ± 0.10 | -0.02 ± 0.10 |
| Medial Height to Posterior Height Ratio (L4) | -0.03 ± 0.13 | 0.04 ± 0.10 |
| Medial Height to Posterior Height Ratio (L5) | 0.02 ± 0.16 | -0.04 ± 0.21 |
| cm | All Vosoritide | Placebo |
|---|---|---|
| Transverse Diameter (L1) | 0.12 ± 0.17 | 0.12 ± 0.11 |
| Transverse Diameter (L2) | 0.12 ± 0.16 | 0.09 ± 0.13 |
| Transverse Diameter (L3) | 0.08 ± 0.15 | 0.09 ± 0.12 |
| Transverse Diameter (L4) | 0.09 ± 0.13 | 0.06 ± 0.11 |
| Transverse Diameter (L5) | 0.10 ± 0.13 | 0.05 ± 0.14 |
Baseline is defined as Day 1 or screening if a Day 1 assessment is not available.
| cm | All Vosoritide | Placebo |
|---|---|---|
| Sagittal Width (L1) | 0.07 ± 0.26 | 0.00 ± 0.22 |
| Sagittal Width (L2) | 0.05 ± 0.18 | 0.01 ± 0.18 |
| Sagittal Width (L3) | 0.08 ± 0.20 | 0.04 ± 0.19 |
| Sagittal Width (L4) | 0.16 ± 0.24 | 0.03 ± 0.16 |
| Sagittal Width (L5) | 0.13 ± 0.34 | 0.06 ± 0.26 |
| Degree | All Vosoritide | Placebo |
|---|---|---|
| Sacral Tilt | 10.6 ± 13.2 | 5.7 ± 15.9 |
| Lordosis Angle | 12.5 ± 17.4 | 8.4 ± 14.2 |
| Kyphosis Angle | -2.2 ± 13.9 | -2.1 ± 10.3 |
Percentages were calculated using the total number of subjects in the safety population (N for each treatment group) as the denominator. All increases are comparing results at Week 52 relative to the baseline assessment.
| Number of participants | All Vosoritide | Placebo |
|---|---|---|
| Increase in sacral tilt (deg) >=5 to <10 | 3 | 6 |
| Increase in sacral tilt (deg) >=10 | 24 | 10 |
| Increase in lordosis angle (deg) >=5 to <10 | 5 | 1 |
| Increase in lordosis angle (deg) >=10 | 19 | 14 |
| Increase in kyphosis angle (deg) >=5 to <10 | 3 | 2 |
| Increase in kyphosis angle (deg) >=10 | 9 | 4 |
| cm^3 | All Vosoritide | Placebo |
|---|---|---|
| Volume of Face | 80.527 ± 59.211 | 78.107 ± 33.369 |
| Volume of Sinus | 2.362 ± 3.578 | 1.195 ± 3.769 |
| Volume of Calvarium | 213.075 ± 202.415 | 183.427 ± 183.210 |
| Whole Brain Total Volume | 175.399 ± 158.088 | 146.247 ± 115.274 |
| Ventricles Total Volume | 11.394 ± 20.416 | 8.515 ± 16.325 |
| percent change | All Vosoritide | Placebo |
|---|---|---|
| Volume of Face | 20.79 ± 18.46 | 19.18 ± 12.22 |
| Volume of sinus | 72.33 ± 100.93 | 81.97 ± 169.74 |
| Volume of Calvarium | 19.41 ± 21.73 | 16.50 ± 19.82 |
| Whole Brain Total Volume | 20.58 ± 21.29 | 16.89 ± 17.22 |
| Ventricles Total Volume | 33.44 ± 52.69 | 30.85 ± 50.65 |
| cm^2 | All Vosoritide | Placebo |
|---|---|---|
| Area of Foramen Magnum | 0.021 ± 0.342 | 0.060 ± 0.203 |
| Area of Spinal Cord at the Foramen Magnum Level | 0.011 ± 0.197 | 0.072 ± 0.163 |
| Percent change | All Vosoritide | Placebo |
|---|---|---|
| Area of Foramen Magnum | 9.19 ± 47.36 | 7.50 ± 19.88 |
| Area of spinal cord at the foramen magnum level | 7.51 ± 33.14 | 19.60 ± 44.26 |
| Ratio | All Vosoritide | Placebo |
|---|---|---|
| Ratio of face volume to calvarium | 0.002 ± 0.031 | 0.003 ± 0.033 |
| Ratio of area of spinal cord to foramen magnum | 0.005 ± 0.120 | 0.037 ± 0.100 |
| Ratio of face volume to sinus | -6.798 ± 175.646 | 14.505 ± 284.950 |
| Percent change | All Vosoritide | Placebo |
|---|---|---|
| Ratio of Face Volume to Calvarium | 0.78 ± 9.06 | 1.31 ± 10.07 |
| Ratio of Area of Spinal Cord to Foramen Magnum | 2.86 ± 23.40 | 9.50 ± 22.68 |
| Ratio of face volume to sinus | -5.37 ± 60.83 | 92.24 ± 341.33 |
| gm | All Vosoritide | Placebo |
|---|---|---|
| GE - Lunar Prodigy: Whole Body Less Head BMC | 55.87 ± 14.68 | 50.26 ± 17.44 |
| Hologic Discovery Horizon Whole Body Less Head BMC | 44.61 ± 12.62 | 47.19 ± 12.55 |
| g/cm^2 | All Vosoritide | Placebo |
|---|---|---|
| GE - Lunar Prodigy Whole Body Less Head BMD | 0.04 ± 0.02 | 0.05 ± 0.03 |
| Hologic Discovery Horizon Whole Body Less Head BMD | 0.03 ± 0.01 | 0.04 ± 0.02 |
| gm | All Vosoritide | Placebo |
|---|---|---|
| GE - Lunar Prodigy Whole Body BMC | 96.85 ± 39.82 | 98.99 ± 32.45 |
| Hologic - Discovery Horizon Whole Body BMC | 87.97 ± 32.35 | 101.33 ± 33.34 |
| gm | All Vosoritide | Placebo |
|---|---|---|
| GE - Lunar Prodigy Lumbar Spine BMC | 2.73 ± 0.83 | 2.09 ± 0.97 |
| Hologic - Discovery Horizon Lumbar Spine BMC | 2.19 ± 0.68 | 1.94 ± 0.72 |
| g/cm^2 | All Vosoritide | Placebo |
|---|---|---|
| GE - Lunar Prodigy Whole Body BMD | 0.06 ± 0.06 | 0.07 ± 0.04 |
| Hologic - Discovery Horizon Whole Body BMD | 0.05 ± 0.02 | 0.07 ± 0.03 |
| g/cm^2 | All Vosoritide | Placebo |
|---|---|---|
| GE - Lunar Prodigy Lumbar Spine BMD | 0.07 ± 0.04 | 0.05 ± 0.03 |
| Hologic - Discovery Horizon Lumbar Spine BMD | 0.05 ± 0.03 | 0.06 ± 0.04 |
Hologic - Discovery Horizon Whole Body BMD Z-Score. Change in whole body bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A whole body BMD Z-score \<-2 SD can indicate low bone density in children. The Whole Body BMD (bone mineral density) z-score compares the BMD to the average bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis.
| Z-score | All Vosoritide | Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Whole Body BMD Z-score | -0.20 ± 0.35 | 0.30 ± 0.47 |
Hologic - Discovery Horizon Lumbar Spine BMD Z-Score Change in lumbar spine bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants lumbar spine BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A BMD Z-score \<-2 SD can indicate low bone density in the lumbar spine in children. The Lumbar Spine BMD (bone mineral density) z-score compares the BMD in the lumbar spine to the average spinal bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis of the spine.
| Z-score | All Vosoritide | Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Lumbar Spine BMD Z-Score | 0.17 ± 0.24 | 0.03 ± 0.45 |
Number of participants with Incidence of Antibody Positivity at Scheduled Visits for : total antibody (TAb), Neutralizing antibodies (NAb), atrial natriuretic peptide (ANP), B-type Natriuretic Peptide (BNP) \& C-type natriuretic peptide (CNP). TAb Titer Positive, NAb Titer Positive, ANP Reactivity Positive, BNP Reactivity Positive \& CNP Reactivity Positive. Day 1 is the baseline assessment result taken prior to first dose of study drug. Ever Positive = the number of participants with at least one positive sample result.
| participants | All Vosoritide | Placebo |
|---|---|---|
| TAb Titer Positive: Day 1 | 0 | 0 |
| TAb Titer Positive: Week 3 | 0 | 0 |
| TAb Titer Positive: Week 13 | 0 | 0 |
| TAb Titer Positive: Week 26 | 2 | 0 |
| TAb Titer Positive: Week 52 | 8 | 0 |
| TAb Titer Ever Positive | 8 | 0 |
| NAb Titer Positive: Day 1 | 0 | 0 |
| NAb Titer Positive: Week 3 | 0 | 0 |
| NAb Titer Positive: Week 13 | 0 | 0 |
| NAb Titer Positive: Week 26 | 0 | 0 |
| NAb Titer Positive: Week 52 | 0 | 0 |
| NAb Titer Ever Positive | 0 | 0 |
| ANP Reactivity Positive: Day 1 | 3 | 5 |
| ANP Reactivity Positive: Week 3 | 0 | 0 |
| ANP Reactivity Positive: Week 13 | 1 | 0 |
| ANP Reactivity Positive: Week 26 | 6 | 0 |
| ANP Reactivity Positive: Week 52 | 11 | 0 |
| ANP Reactivity Ever Positive | 12 | 0 |
| BNP Reactivity Positive: Day 1 | 0 | 3 |
| BNP Reactivity Positive: Week 3 | 0 | 0 |
| BNP Reactivity Positive: Week 13 | 2 | 0 |
| BNP Reactivity Positive: Week 26 | 3 | 0 |
| BNP Reactivity Positive: Week 52 | 2 | 0 |
| BNP Reactivity Ever Positive | 3 | 0 |
| CNP Reactivity Positive: Day 1 | 0 | 1 |
| CNP Reactivity Positive: Week 3 | 0 | 0 |
| CNP Reactivity Positive: Week 13 | 1 | 0 |
| CNP Reactivity Positive: Week 26 | 2 | 0 |
| CNP Reactivity Positive: Week 52 | 4 | 0 |
| CNP Reactivity Ever Positive | 4 | 0 |
| U/L | All Vosoritide | Placebo |
|---|---|---|
| BSAP: Baseline | 140.28 ± 183.23 | 113.43 ± 33.56 |
| BSAP: Day 8 | 122.32 ± 99.09 | 104.12 ± 29.12 |
| BSAP: Change from baseline to Day 8 | -19.39 ± 202.90 | -7.67 ± 17.53 |
| BSAP: Week 6 | 130.38 ± 140.08 | 109.46 ± 29.04 |
| BSAP: Change from baseline to Week 6 | 2.63 ± 218.60 | -6.17 ± 24.32 |
| BSAP: Week 20 | 109.67 ± 30.88 | 104.46 ± 29.69 |
| BSAP: Change from baseline to Week 20 | -7.21 ± 96.94 | -11.32 ± 18.19 |
| BSAP: Week 39 | 108.49 ± 32.02 | 208.13 ± 363.56 |
| BSAP: Change from baseline to Week 39 | -12.21 ± 105.04 | 95.41 ± 352.78 |
| ng/ mmol Cr | All Vosoritide | Placebo |
|---|---|---|
| Biomarker: Type II Collagen C-Telopeptides Normalized for Creatinine (CTX-II) | -9364.7 ± 65244.1 | -7607.6 ± 54614.9 |
| nM | All Vosoritide | Placebo |
|---|---|---|
| Biomarker: Plasma Cyclic Guanosine Monophosphate (cGMP) Change From Pre-Dose to Maximum Post-Dose at Week 52 | 39.079 ± 25.706 | 9.460 ± 26.307 |
Laboratory results up to 30 days after study drug discontinuation were included. Baseline is the last measurement prior to the initiation of study drug.
| pg/mL | All Vosoritide | Placebo |
|---|---|---|
| CNP Col X BM: Baseline | 9833.8 ± 3444.7 | 9555.0 ± 4016.7 |
| CNP Col X BM: Day 8 | 12093.8 ± 4443.8 | 10017.5 ± 3831.2 |
| CNP Col X BM: Change from baseline to Day 8 | 2139.5 ± 3871.9 | 1391.3 ± 3354.2 |
| CNP Col X BM: Week 6 | 13456.3 ± 4763.3 | 9464.8 ± 4243.3 |
| CNP Col X BM: Change from baseline to Week 6 | 3400.3 ± 4554.6 | 200.3 ± 3867.5 |
| CNP Col X BM: Week 20 | 12833.3 ± 4581.9 | 12064.8 ± 5277.3 |
| CNP Col X BM: Change from baseline to Week 20 | 2928.0 ± 4385.9 | 2435.5 ± 4666.9 |
| CNP Col X BM: Week 39 | 12249.7 ± 5056.5 | 9932.7 ± 4004.4 |
| CNP Col X BM: Change from baseline to Week 39 | 2362.8 ± 5752.9 | 946.4 ± 3490.1 |
Sleep-testing device was used to assess presence \& severity of sleep-disordered breathing by measurement of blood oxygen(O2)saturation,pulse rate,\& airflow during overnight monitoring Episodes(Epi) of sleep apnea variables summarized as: Number(No.)of epi of apnea/hr(AI);No.of epi of hypopnea/hr(HI);No.of epi of obstructive apnea hypopneas/hr(AHI);No.of epi of obstructive apneas/hr(Obstructive Apnea Index);No.of epi of central apneas/hr(CAI);No.of desaturations/hr \>=3% AHI is a marker of obstructive sleep apnea (OSA), scored as No.of apnea or hypopnea epi/hr, with AHI \<=1/hr normal, 1\< AHI\<=5 mild,5\< AHI \<=10 moderate,\& AHI\>10/hr severe OSA. CAI reflects cervical cord compression at cervical-medullary junction, \& is No. of epi of a pause in ventilation with no associated respiratory effort, with\> 5 epi/hr abnormal.O2 desaturation index measures average No. of desaturation epi/hr, defined as decrease in O2 saturation of \>=3% for at least 10sec, with(\<8/hr normal \& \>=8/hr abnormal
| Events per hour | Cohort 1: Placebo | Cohort 1: Vosoritide | Cohort 2: Placebo | Cohort 2: Vosoritide | Cohort 3: Placebo | Cohort 3: Vosoritide |
|---|---|---|---|---|---|---|
| Apnea Hypopnea Index (AHI) | -0.54 ± 2.70 | -1.45 ± 4.63 | 1.06 ± 4.80 | -0.72 ± 1.41 | 1.89 ± 6.31 | -0.94 ± 2.78 |
| Apnea Index (AI) | -1.07 ± 2.12 | -0.83 ± 1.93 | 0.40 ± 2.34 | -0.71 ± 1.61 | -1.09 ± 1.22 | -0.36 ± 2.54 |
| Central Apnea Index (CAI) | -1.26 ± 2.66 | -0.74 ± 1.86 | -0.28 ± 0.89 | -0.71 ± 1.61 | -1.00 ± 0.97 | 0.50 ± 0.92 |
| Hypopnea Index (HI) | 0.52 ± 1.35 | -0.61 ± 3.63 | 0.66 ± 2.53 | -0.01 ± 1.32 | 2.97 ± 5.45 | -0.56 ± 0.54 |
| Desaturation per Hour >=3% | -0.41 ± 1.51 | -1.24 ± 3.98 | 0.98 ± 3.60 | -0.69 ± 1.30 | 1.71 ± 6.63 | -0.93 ± 2.60 |
| Obstructive Index | 0.19 ± 0.73 | -0.09 ± 0.45 | 0.68 ± 1.52 | -0.01 ± 0.08 | -0.07 ± 0.64 | -0.86 ± 2.08 |
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞ excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
| min*pg/ml | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 149000 ± 98000 |
| Cohort 1 15 μg/kg/day: Week 13 | 197000 ± 144000 |
| Cohort 1 15 μg/kg/day: Week 26 | 306000 ± 252000 |
| Cohort 1 15 μg/kg/day: Week 39 | 284000 ± 137000 |
| Cohort 1 15 μg/kg/day: Week 52 | 303000 ± 208000 |
| Cohort 2 15 μg/kg/day: Day 01 | 102000 ± NA |
| Cohort 2 15 μg/kg/day: Week 13 | 74500 ± NA |
| Cohort 2 15 μg/kg/day: Week 26 | 233000 ± 132000 |
| Cohort 2 15 μg/kg/day: Week 39 | 204000 ± 39700 |
| Cohort 2 15 μg/kg/day: Week 52 | 137000 ± 48900 |
| Cohort 2 30 μg/kg/day: Day 01 | 557000 ± 278000 |
| Cohort 2 30 μg/kg/day: Week 13 | 670000 ± 312000 |
| Cohort 2 30 μg/kg/day: Week 26 | 429000 ± 163000 |
| Cohort 2 30 μg/kg/day: Week 39 | 387000 ± 53800 |
| Cohort 2 30 μg/kg/day: Week 52 | 768000 ± 391000 |
| Cohort 3 30 μg/kg/day: Day 01 | 353000 ± 133000 |
| Cohort 3 30 μg/kg/day: Week 13 | 382000 ± 268000 |
| Cohort 3 30 μg/kg/day: Week 26 | 305000 ± 82100 |
| Cohort 3 30 μg/kg/day: Week 39 | 575000 ± 455000 |
| Cohort 3 30 μg/kg/day: Week 52 | 622000 ± 455000 |
| min*pg/ml | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 134000 ± 96500 |
| Cohort 1 15 μg/kg/day: Week 13 | 183000 ± 126000 |
| Cohort 1 15 μg/kg/day: Week 26 | 283000 ± 222000 |
| Cohort 1 15 μg/kg/day: Week 39 | 257000 ± 132000 |
| Cohort 1 15 μg/kg/day: Week 52 | 260000 ± 172000 |
| Cohort 2 15 μg/kg/day: Day 01 | 83100 ± 48300 |
| Cohort 2 15 μg/kg/day: Week 13 | 115000 ± 59300 |
| Cohort 2 15 μg/kg/day: Week 26 | 197000 ± 121000 |
| Cohort 2 15 μg/kg/day: Week 39 | 166000 ± 81000 |
| Cohort 2 15 μg/kg/day: Week 52 | 125000 ± 76700 |
| Cohort 2 30 μg/kg/day: Day 01 | 525000 ± 251000 |
| Cohort 2 30 μg/kg/day: Week 13 | 642000 ± 353000 |
| Cohort 2 30 μg/kg/day: Week 26 | 408000 ± 148000 |
| Cohort 2 30 μg/kg/day: Week 39 | 365000 ± 44700 |
| Cohort 2 30 μg/kg/day: Week 52 | 670000 ± 335000 |
| Cohort 3 30 μg/kg/day: Day 01 | 312000 ± 119000 |
| Cohort 3 30 μg/kg/day: Week 13 | 342000 ± 245000 |
| Cohort 3 30 μg/kg/day: Week 26 | 300000 ± 79100 |
| Cohort 3 30 μg/kg/day: Week 39 | 591000 ± 359000 |
| Cohort 3 30 μg/kg/day: Week 52 | 558000 ± 400000 |
| min*pg/ml | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 132000 ± 97300 |
| Cohort 1 15 μg/kg/day: Week 13 | 182000 ± 127000 |
| Cohort 1 15 μg/kg/day: Week 26 | 282000 ± 222000 |
| Cohort 1 15 μg/kg/day: Week 39 | 256000 ± 132000 |
| Cohort 1 15 μg/kg/day: Week 52 | 258000 ± 169000 |
| Cohort 2 15 μg/kg/day: Day 01 | 65900 ± 33600 |
| Cohort 2 15 μg/kg/day: Week 13 | 112000 ± 62900 |
| Cohort 2 15 μg/kg/day: Week 26 | 196000 ± 121000 |
| Cohort 2 15 μg/kg/day: Week 39 | 165000 ± 82400 |
| Cohort 2 15 μg/kg/day: Week 52 | 122000 ± 75700 |
| Cohort 2 30 μg/kg/day: Day 01 | 547000 ± 279000 |
| Cohort 2 30 μg/kg/day: Week 13 | 645000 ± 357000 |
| Cohort 2 30 μg/kg/day: Week 26 | 407000 ± 148000 |
| Cohort 2 30 μg/kg/day: Week 39 | 365000 ± 44300 |
| Cohort 2 30 μg/kg/day: Week 52 | 672000 ± 334000 |
| Cohort 3 30 μg/kg/day: Day 01 | 323000 ± 129000 |
| Cohort 3 30 μg/kg/day: Week 13 | 340000 ± 244000 |
| Cohort 3 30 μg/kg/day: Week 26 | 297000 ± 80700 |
| Cohort 3 30 μg/kg/day: Week 39 | 567000 ± 361000 |
| Cohort 3 30 μg/kg/day: Week 52 | 557000 ± 401000 |
| pg/ml | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 4430 ± 3670 |
| Cohort 1 15 μg/kg/day: Week 13 | 4350 ± 1670 |
| Cohort 1 15 μg/kg/day: Week 26 | 5850 ± 3260 |
| Cohort 1 15 μg/kg/day: Week 39 | 5600 ± 2200 |
| Cohort 1 15 μg/kg/day: Week 52 | 5640 ± 2740 |
| Cohort 2 15 μg/kg/day: Day 01 | 2840 ± 1230 |
| Cohort 2 15 μg/kg/day: Week 13 | 5970 ± 2390 |
| Cohort 2 15 μg/kg/day: Week 26 | 6800 ± 3360 |
| Cohort 2 15 μg/kg/day: Week 39 | 4600 ± 2150 |
| Cohort 2 15 μg/kg/day: Week 52 | 3870 ± 2120 |
| Cohort 2 30 μg/kg/day: Day 01 | 14500 ± 5950 |
| Cohort 2 30 μg/kg/day: Week 13 | 13400 ± 6070 |
| Cohort 2 30 μg/kg/day: Week 26 | 10100 ± 2970 |
| Cohort 2 30 μg/kg/day: Week 39 | 6980 ± 1140 |
| Cohort 2 30 μg/kg/day: Week 52 | 12900 ± 6260 |
| Cohort 3 30 μg/kg/day: Day 01 | 13400 ± 5710 |
| Cohort 3 30 μg/kg/day: Week 13 | 10500 ± 6850 |
| Cohort 3 30 μg/kg/day: Week 26 | 11500 ± 4290 |
| Cohort 3 30 μg/kg/day: Week 39 | 18400 ± 11900 |
| Cohort 3 30 μg/kg/day: Week 52 | 13500 ± 6770 |
| min | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 13.1 ± 6.33 |
| Cohort 1 15 μg/kg/day: Week 13 | 14.3 ± 5.5 |
| Cohort 1 15 μg/kg/day: Week 26 | 16.1 ± 8.69 |
| Cohort 1 15 μg/kg/day: Week 39 | 17.4 ± 11.9 |
| Cohort 1 15 μg/kg/day: Week 52 | 16.1 ± 6.27 |
| Cohort 2 15 μg/kg/day: Day 01 | 11.3 ± 6.35 |
| Cohort 2 15 μg/kg/day: Week 13 | 6 ± 1.41 |
| Cohort 2 15 μg/kg/day: Week 26 | 10.8 ± 5.5 |
| Cohort 2 15 μg/kg/day: Week 39 | 15.4 ± 11.6 |
| Cohort 2 15 μg/kg/day: Week 52 | 14.2 ± 5.76 |
| Cohort 2 30 μg/kg/day: Day 01 | 12.9 ± 9.1 |
| Cohort 2 30 μg/kg/day: Week 13 | 14 ± 8.42 |
| Cohort 2 30 μg/kg/day: Week 26 | 12 ± 5.2 |
| Cohort 2 30 μg/kg/day: Week 39 | 15 ± 0 |
| Cohort 2 30 μg/kg/day: Week 52 | 14.3 ± 1.53 |
| Cohort 3 30 μg/kg/day: Day 01 | 7.36 ± 3.53 |
| Cohort 3 30 μg/kg/day: Week 13 | 9.43 ± 5.22 |
| Cohort 3 30 μg/kg/day: Week 26 | 9 ± 4.69 |
| Cohort 3 30 μg/kg/day: Week 39 | 11.3 ± 3.59 |
| Cohort 3 30 μg/kg/day: Week 52 | 14.5 ± 3.51 |
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
| ml/min/kg | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 134 ± 59.8 |
| Cohort 1 15 μg/kg/day: Week 13 | 111 ± 58.5 |
| Cohort 1 15 μg/kg/day: Week 26 | 79.8 ± 48.3 |
| Cohort 1 15 μg/kg/day: Week 39 | 65.3 ± 32.7 |
| Cohort 1 15 μg/kg/day: Week 52 | 69 ± 41.2 |
| Cohort 2 15 μg/kg/day: Day 1 | 147 ± NA |
| Cohort 2 15 μg/kg/day: Week 13 | 201 ± NA |
| Cohort 2 15 μg/kg/day: Week 26 | 79.5 ± 38.4 |
| Cohort 2 15 μg/kg/day: Week 39 | 75.5 ± 14.8 |
| Cohort 2 15 μg/kg/day: Week 52 | 122 ± 52.5 |
| Cohort 2 30 μg/kg/day: Day 01 | 65.9 ± 31.6 |
| Cohort 2 30 μg/kg/day: Week 13 | 58.7 ± 40.4 |
| Cohort 2 30 μg/kg/day: Week 26 | 79.4 ± 37.7 |
| Cohort 2 30 μg/kg/day: Week 39 | 78.3 ± 10.9 |
| Cohort 2 30 μg/kg/day: Week 52 | 49.7 ± 32 |
| Cohort 3 30 μg/kg/day: Day 01 | 95.9 ± 34 |
| Cohort 3 30 μg/kg/day: Week 13 | 115 ± 78.1 |
| Cohort 3 30 μg/kg/day: Week 26 | 104 ± 23.2 |
| Cohort 3 30 μg/kg/day: Week 39 | 73.6 ± 41.6 |
| Cohort 3 30 μg/kg/day: Week 52 | 76.5 ± 49.8 |
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. V/F excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
| ml/kg | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 4070 ± 2310 |
| Cohort 1 15 μg/kg/day: Week 13 | 3990 ± 2960 |
| Cohort 1 15 μg/kg/day: Week 26 | 3400 ± 2520 |
| Cohort 1 15 μg/kg/day: Week 39 | 2330 ± 1150 |
| Cohort 1 15 μg/kg/day: Week 52 | 2660 ± 1420 |
| Cohort 2 15 μg/kg/day: Day 01 | 5550 ± NA |
| Cohort 2 15 μg/kg/day: Week 13 | 7810 ± NA |
| Cohort 2 15 μg/kg/day: Week 26 | 3890 ± 2880 |
| Cohort 2 15 μg/kg/day: Week 39 | 2250 ± 284 |
| Cohort 2 15 μg/kg/day: Week 52 | 3770 ± 1410 |
| Cohort 2 30 μg/kg/day: Day 01 | 3190 ± 1790 |
| Cohort 2 30 μg/kg/day: Week 13 | 2090 ± 1360 |
| Cohort 2 30 μg/kg/day: Week 26 | 1960 ± 829 |
| Cohort 2 30 μg/kg/day: Week 39 | 2920 ± 205 |
| Cohort 2 30 μg/kg/day: Week 52 | 3040 ± 2630 |
| Cohort 3 30 μg/kg/day: Day 01 | 5240 ± 1890 |
| Cohort 3 30 μg/kg/day: Week 13 | 4260 ± 2960 |
| Cohort 3 30 μg/kg/day: Week 26 | 2750 ± 710 |
| Cohort 3 30 μg/kg/day: Week 39 | 2200 ± 951 |
| Cohort 3 30 μg/kg/day: Week 52 | 2620 ± 1950 |
Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.
| min | All Vosoritide |
|---|---|
| Cohort 1 15 μg/kg/day: Day 01 | 21.7 ± 7.99 |
| Cohort 1 15 μg/kg/day: Week 13 | 25.4 ± 10.7 |
| Cohort 1 15 μg/kg/day: Week 26 | 29.2 ± 7.06 |
| Cohort 1 15 μg/kg/day: Week 39 | 25.7 ± 7.82 |
| Cohort 1 15 μg/kg/day: Week 52 | 29 ± 9.12 |
| Cohort 2 15 μg/kg/day: Day 01 | 26.1 ± NA |
| Cohort 2 15 μg/kg/day: Week 13 | 26.9 ± NA |
| Cohort 2 15 μg/kg/day: Week 26 | 32.7 ± 9.62 |
| Cohort 2 15 μg/kg/day: Week 39 | 20.9 ± 2.18 |
| Cohort 2 15 μg/kg/day: Week 52 | 24 ± 12.8 |
| Cohort 2 30 μg/kg/day: Day 01 | 33.3 ± 8.41 |
| Cohort 2 30 μg/kg/day: Week 13 | 25.6 ± 3.59 |
| Cohort 2 30 μg/kg/day: Week 26 | 21 ± 13.1 |
| Cohort 2 30 μg/kg/day: Week 39 | 26.2 ± 5.46 |
| Cohort 2 30 μg/kg/day: Week 52 | 40.1 ± 15.2 |
| Cohort 3 30 μg/kg/day: Day 01 | 41.1 ± 18.8 |
| Cohort 3 30 μg/kg/day: Week 13 | 26.2 ± 7.1 |
| Cohort 3 30 μg/kg/day: Week 26 | 19.2 ± 6.14 |
| Cohort 3 30 μg/kg/day: Week 39 | 22.7 ± 5.36 |
| Cohort 3 30 μg/kg/day: Week 52 | 24.3 ± 6.58 |
Collected over Up to Week 56 Safety Follow-Up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/32 (0%) | 6/32 (18.8%) | 32/32 (100%) |
| Vosoritide | 1/43 (2.3%) | 3/43 (7%) | 43/43 (100%) |
| Event | Placebo | Vosoritide |
|---|---|---|
| Petit mal epilepsyNervous system disorders | 1/32 | 0/43 |
| GastroenteritisInfections and infestations | 1/32 | 0/43 |
| Autism spectrum disordePsychiatric disorders | 1/32 | 0/43 |
| Otitis mediaInfections and infestations | 1/32 | 0/43 |
| Parainfluenzae virus infectionInfections and infestations | 1/32 | 0/43 |
| VomitingGastrointestinal disorders | 1/32 | 0/43 |
| Skull fractureInjury, poisoning and procedural complications | 1/32 | 0/43 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/32 | 0/43 |
| Oxygen saturation decreasedInvestigations | 0/32 | 1/43 |
| PneumoniaInfections and infestations | 0/32 | 1/43 |
| Event | Placebo | Vosoritide |
|---|---|---|
| Injection site reactionGeneral disorders | 13/32 | 34/43 |
| Injection site erythemaGeneral disorders | 13/32 | 33/43 |
| Viral infectionInfections and infestations | 4/32 | 8/43 |
| Injection site swellingGeneral disorders | 2/32 | 8/43 |
| FallInjury, poisoning and procedural complications | 3/32 | 7/43 |
| Injection site urticariaGeneral disorders | 1/32 | 6/43 |
| Arthropod biteInjury, poisoning and procedural complications | 2/32 | 6/43 |
| Injection site indurationGeneral disorders | 0/32 | 5/43 |
| ConstipationGastrointestinal disorders | 2/32 | 5/43 |
| RhinitisInfections and infestations | 0/32 | 4/43 |
FAS Population: The Full Analysis Set (FAS) was defined according to the intent-to-treat principle and included all enrolled sentinel and randomized participants with a signed informed consent.
| Age, Continuous(Months) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Mean | 23.4 ± 21.0 | 23.0 ± 16.9 | 26.5 ± 19.3 | 24.5 ± 18.4 |
| Age, Continuous(Months) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Mean | 24.71 ± 20.79 | 24.39 ± 16.83 | 27.82 ± 19.25 | 25.90 ± 18.30 |
| Sex: Female, Male(Participants) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Female | 3 | 15 | 19 | 37 |
| Male | 8 | 17 | 13 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 | 6 |
| Not Hispanic or Latino | 11 | 29 | 29 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| White | 8 | 21 | 25 | 54 |
| Asian-Other | 1 | 6 | 2 | 9 |
| Asian-Japanese | 0 | 4 | 4 | 8 |
| Multiple | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Weight(Kg) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Mean | 10.12 ± 3.70 | 10.20 ± 3.83 | 10.55 ± 4.31 | 10.34 ± 3.98 |
| Weight Z-Score(Z-Score) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Mean | -1.41 ± 0.73 | -1.49 ± 1.26 | -1.59 ± 1.44 | -1.52 ± 1.27 |
| BMI(kg/m^2) | Sentinel | Randomized Vosoritide | Randomized Placebo | Total |
|---|---|---|---|---|
| Mean | 20.06 ± 1.87 | 19.48 ± 2.45 | 20.14 ± 2.39 | 19.85 ± 2.34 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Jan 2022, 43 months.
Results were first posted in Jun 2024, 2 years 4 months after primary completion. A results delay was requested in Dec 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vosoritide